RELB and breast cancer: Here we identify PAK4 as an attractive breast cancer drug target candidate given its overexpression in breast cancer patients negatively affecting prognosis and its key function in evading senescence-like growth arrest in breast cancer cells via the noncanonical NF-κB component RELB.